Back to top

Analyst Blog

Theravance Inc. (THRX - Analyst Report) recently announced that the US Food and Drug Administration (FDA) has approved the company’s marketed product, Vibativ (telavancin), for an additional indication.

The FDA approved Vibativ for treating adults suffering from hospital-acquired and ventilator-associated bacterial pneumonia. The disease is also known as nosocomial pneumonia (NP). Approval was gained for treating the disease caused by susceptible isolates of staphylococcus aureus in the absence of suitable alternatives.

Following the approval, Theravance intends to launch the drug for the new indication in the third quarter of 2013. The FDA approved Vibativ for the new indication on the basis of data from two phase III studies (ATTAIN I and II).

We note that Vibativ is already approved in the US for treating adults with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of gram-positive bacteria, including both methicillin-resistant and methicillin-susceptible strains of staphylococcus aureus. Vibativ is also marketed in Canada for cSSSI.

In Nov 2012, an advisory panel of FDA issued a 13-2 favorable vote about the safety and efficacy of the drug for the NP indication due to susceptible isolates of gram-positive microorganisms in the absence of suitable alternatives. The panel did not recommend the drug as a first-line treatment for NP. The FDA approval was also for the limited indication.

We believe that the label expansion of the drug for a limited indication will restrict the drug’s sales potential. Consequently, we do not expect the FDA decision to boost Theravance’s top line significantly.

Theravance, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Biopharma companies that currently look more attractive include Jazz Pharmaceuticals (JAZZ - Analyst Report), Cytokinetics, Inc. (CYTK - Snapshot Report) and Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report). While Jazz Pharma is a Zacks Rank #1 (Strong Buy) stock, Cytokinetics and Alexion Pharma carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%